Introduction
============

Barrett's esophagus (BE) is a metaplastic condition in which squamous epithelium is replaced by specialized intestinal columnar epithelium [@JR1691-1] and is the only known histological precursor to esophageal adenocarcinoma. Multiple endoscopic therapies, including both ablative and resection techniques, have been shown to be safe and effective for BE-associated neoplasia [@JR1691-2] [@JR1691-3] [@JR1691-4] [@JR1691-5] . While radiofrequency ablation (RFA) is currently the first-line ablative therapy for treatment of BE [@JR1691-2] [@JR1691-3] , endoscopic cryotherapy, a technique that induces tissue injury via rapid intracellular freezing [@JR1691-6] , has become an attractive alternative. Indeed, cryotherapy has been shown to be effective in achieving complete eradication of intestinal metaplasia (CE-IM) and dysplasia (CE-D) in 46 % and 76 % of patients with BE after failed RFA [@JR1691-7] .

A novel contact balloon cryoablation (BC) system was recently introduced for management of BE-associated neoplasia (CryoBalloon, Pentax Medical, Redwood City, California, United States) [@JR1691-8] . The new system consists of a portable hand-held device that converts liquid nitrous oxide into its gaseous form within a contact balloon system [@JR1691-8] . Potential advantages of BC include its portability, ease of use, consistent cryogen dosing delivery to the target site, and lower costs when compared to other existing ablation systems [@JR1691-9] . Furthermore, the new system does not require any capital equipment acquisition which may facilitate usability and introduction in various practice settings. Utilizing this novel technologic intervention should lead to high rates of CE-IM and CE-D in patients with BE. The aim of this study was to determine the safety and effectiveness of BC for the treatment of BE by performing a meta-analysis of the available literature.

Patients and methods
====================

Search strategy
---------------

We identified studies by performing a systematic literature search of electronic databases (PubMed, Web of Science, Google Scholar, EMBASE) from their inception through June 2019, with the assistance of a medical librarian. Searches were performed using a combination of the following terms: C2 cryoballoon\*, cryoballoon ablation barrett\*, barrett cryotherapy\*, cryoballoon ablation esophagus\*, cryoballoon ablation device\*, barrett esophagus, cryoablat\*, cryo\*, freeze\*, cryoballoon focal\*, focal cryoablation\*. The search query results were reviewed by three investigators (DRW, NK, DY) for relevance based on the pre-established inclusion and exclusion criteria. The full-text of the pertinent studies were then reviewed by the investigators for data extraction and analysis. We attempted to identify any additional studies by also reviewing the bibliographies of the included studies and by performing a manual search to retrieve other potentially relevant studies that may have been omitted on our initial search strategy. Any discrepancies were resolved by consensus and/or by consulting a fourth investigator (PVD).

Study selection
---------------

Three investigators (DRW, NK, DY) screened all titles and abstracts for studies reporting outcomes of CryoBalloon ablation in BE. The articles were reviewed in full text and included in the meta-analysis if they met the following pre-defined inclusion criteria: (1) studies included at least five patients with BE treated with cryotherapy via CryoBalloon device, (2) studies reported the rate of CE-IM and/or CE-D after at least one cryotherapy treatment session. Studies were excluded if: (1) there were less than five patients included in the study; (2) cryotherapy was performed with a device other than the balloon-based liquid nitrous oxide; (3) CE-IM or CE-D could not be determined; (4) the study was a commentary, review, or survey; (5) duplicate studies; or (6) publication was in a language other than English.

Data extraction and quality assessment
--------------------------------------

Two investigators (DRW, DY) independently extracted data from each study by using a standardized abstraction form. The standardized data abstraction form included: (1) authors; (2) year of publication; (3) setting; (4) study design; (5) number of patients and baseline characteristics; (6) length of BE segment; (7) prior treatments (e. g. RFA, EMR); (8) procedure characteristics (procedure time, number of ablation sessions), (9) adverse events (AEs); (10) rate of CE-IM and CE-D; and (11) follow-up period.

Quality of the studies was formally evaluated by two investigators (DRW, DY) by using a modified Newcastle Ottawa Scale (NOS) for cohort studies as previously described [@JR1691-7] [@JR1691-10] , consisting of six components, each valued up to 1 point: cohort size, length of BE segment, histopathology prior to cryotherapy, endoscopic therapy prior to cryotherapy, number of cryotherapy sessions before assessment of outcomes, and adequacy of follow-up. Studies with scores \> 3 or ≤ 3 were considered to be of high or low quality, respectively. Funnel plots were generated to evaluate for publication bias [@JR1691-11] . Any discrepancies were resolved by input by a third investigator (PVD) with general consensus among all of the investigators.

Outcome measures and data analysis
----------------------------------

The primary aims of this study were to identify the rate of CE-IM an CE-D among patients with BE after cryotherapy with the balloon-based liquid nitrous oxide device (CryoBalloon). Secondary outcomes included technical feasibility and rate of adverse events. Technical feasibility was defined as the ability to complete the ablation session as intended. AEs included in the standardized abstraction form included perforation, mucosal laceration/injury, bleeding, and stricture formation.

Statistical analysis
--------------------

This study was performed in accordance with the criteria established in the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) and Meta-analyses of Observational studies in Epidemiology (MOOSE) checklists [@JR1691-12] [@JR1691-13] . Pooled proportions for the outcome measures were calculated using a random effects model to account for differences in study size. The Cochran Q test and I ^2^ were used to assess for heterogeneity among the included studies. I ^2^ values of \< 25 %, 25 % to 50 % and \> 50 % were considered to represent low, moderate and high heterogeneity, respectively. *P*  \< 0.05 was considered significant and all tests were two-tailed. Prediction intervals for the net effect were calculated for feasibility, CE-IM, and CE-D [@JR1691-14] . Analysis was conducted using Stata, version 15 (Stata Corp, College Station, Texas, United States).

Results
=======

Search results
--------------

Our search strategy yielded 1407 studies, of which 604 were duplicates. Of the remaining 803 studies, 793 were deemed irrelevant based on title and abstract review. Full review was subsequently performed on 11 studies. Of these, three case reports (\< 5 patients) were excluded [@JR1691-15] [@JR1691-16] [@JR1691-17] ; and one study was excluded because it reported outcomes of CryoBalloon ablation in squamous cell cancer of the esophagus [@JR1691-18] . The remaining seven studies fulfilled the predefined inclusion and exclusion criteria for meta-analysis ( [Fig. 1](#FI1691-1){ref-type="fig"} ) [@JR1691-9] [@JR1691-19] [@JR1691-20] [@JR1691-21] [@JR1691-22] [@JR1691-23] [@JR1691-24] .

![PRISMA flow diagram. From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(7): e1000097. doi:10.1371/journal.pmed1000097](10-1055-a-1067-4520-i1691ei1){#FI1691-1}

Study characteristics and quality assessment
--------------------------------------------

All studies were observational, from the United States and the Netherlands, and published between 2015 to 2019 ( [Table 1](#TB1691-1){ref-type="table"} ). Most studies were single-center in design (n = 5). Three studies were published in abstract form as compared to four studies published in full text. The seven studies cumulatively reported outcomes in 272 patients with BE treated with CryoBalloon ablation. Most patients were men (198/272; 72.8 %) and older. The Prague classification was provided in 5 studies; with 3 studies reporting mean and/or median lengths of BE consistent with long-segment BE (≥ 3 cm). Two studies excluded patients with prior RFA treatment [@JR1691-19] [@JR1691-24] , three studies included patients with prior RFA [@JR1691-9] [@JR1691-22] [@JR1691-23] , whereas status of RFA was not specified in the remainder two studies [@JR1691-20] [@JR1691-21] . Most studies (n = 5) reported whether EMR was performed as part of the management of BE patients with visible lesions. In aggregate, the most common histopathology reported prior to CryoBalloon ablation was high-grade dysplasia (n = 131), followed by low-grade dysplasia (n = 75), and intramucosal adenocarcinoma (n = 52). Ablation was reported in nine patients with no dysplasia and in one patient with indefinite dysplasia. Liquid nitrogen application duration of 10 seconds was utilized in all studies except one [@JR1691-23] , which also included ablation durations of 6 and 8 seconds. In five of seven studies, outcomes were assessed following a single ablation session.

###### Study and patient characteristics.

  Study                           Publication type   Study design       Number of patients   Age (years)   Male/female   Prague C&M criteria   Prior treatment (n)   Baseline histopathology   Number of ablation sessions   Cryotherapy dosimetry                               
  ------------------------------- ------------------ ------------------ -------------------- ------------- ------------- --------------------- --------------------- ------------------------- ----------------------------- ----------------------- ---- ---- ---- ------------ -------------------------------------------
  Scholvinck 2015 [@JR1691-13]    Full text          MC prospective      39                  66 (median)    35/4         2 (median)            5 (median)             0                        12                            10                       9    9   11   1            6 s (n = 10), 8 s (n = 28), 10 s (n = 18)
  Wang 2015 [@JR1691-14]          Abstract           SC retrospective     5                  65 (median)   NR            NR                    NR                    NR                        NR                            --                      --    5   --   1            10 s
  Sitaraman 2016 [@JR1691-15]     Abstract           SC retrospective    17                  NR            NR            NR                    NR                    NR                        NR                            --                       2   12    3   1            10 s
  Kunzli 2017 [@JR1691-16]        Full text          SC prospective      30                  66 (median)    26/4         0 (median)            0 (median)            23                        15                            --                      14    7    9   1            10 s
  Van Munster 2018 [@JR1691-17]   Full text          SC retrospective    20                  66 (median)    17/3         0 (mean)              2 (mean)               8                        10                            --                       9   11   --   1            10 s
  Canto 2018 [@JR1691-9]          Full text          SC prospective      41                  65.6 (mean)    19/22        1.7 (mean)            3.9 (mean)            19                        14                            --                      13   23    5   3 (median)   10 s
  Canto 2019 [@JR1691-18]         Abstract           MC prospective     120                  64.7 (mean)   101/19        1 (mean)              3 (mean)               0                        54                            --                      28   64   23   2 (median)   10 s

C, circumferential extent of disease; M, maximum extent of disease; RFA, radiofrequency ablation; EMR, endoscopic mucosal resection; HGD, high-grade dysplasia; ID, infectious disease; IMC, imaging mass cytometry; LGD, low-grade dysplasia; MC, multicenter; ND no evidence of disease; NR, no response; SC, single-center

Quality assessment of the included studies were evaluated by using the modified NOS scale as shown in [Table 2](#TB1691-2){ref-type="table"} . Overall, five studies were found to be of high quality and two studies were deemed low quality based on our scale ( **Supplemental Table 1** ).

###### Assessment of study quality with modified Newcastle-Ottawa Scale.

  Study                           Large cohort size   Length of BE segment   Baseline histopathology   RFA/EMR prior to cryotherapy   No. cryotherapy sessions/dosimetry   Adequacy of follow-Up   Total
  ------------------------------- ------------------- ---------------------- ------------------------- ------------------------------ ------------------------------------ ----------------------- -------
  Scholvinck 2015 [@JR1691-13]    1                   1                      1                         1                              0                                    1                       5
  Wang 2015 [@JR1691-14]          0                   0                      1                         0                              1                                    0                       2
  Sitaraman 2016 [@JR1691-15]     0                   0                      1                         0                              1                                    0                       2
  Kunzli 2017 [@JR1691-16]        1                   1                      1                         1                              1                                    1                       6
  Van Munster 2018 [@JR1691-17]   0                   1                      1                         1                              1                                    1                       5
  Canto 2018 [@JR1691-9]          1                   1                      1                         1                              1                                    1                       6
  Canto 2019 [@JR1691-18]         1                   1                      1                         1                              1                                    0                       5

BE, Barrett's esophagus; RFA, radiofrequency ablation; EMR, endoscopic mucosal resection

Main outcomes
-------------

### Technical feasibility

The seven studies cumulatively reported 548 ablation sessions in 272 patients. The pooled rate of technical success, defined as completion of the ablation procedure as intended, was 95.8 % (95 % CI: 93.6--97.5 %; *P*  = 0.3) with I ^2^  = 13.2 % in the random effects model ( [Fig. 2a](#FI1691-2){ref-type="fig"} ). The 95 % prediction interval was calculated to be 0.85--0.95. Reasons for failed cryoablation included: difficult positioning of the balloon at the gastroesophageal junction (n = 2) [@JR1691-19] [@JR1691-22] , pre-existing stricture (n = 3) [@JR1691-9] [@JR1691-19] [@JR1691-21] , ablation of non-BE mucosa (n = 1) [@JR1691-19] , and device failure (n = 3) [@JR1691-19] . There was no evidence of substantial publication bias based on visual inspection of the funnel plot ( [Fig. 3a](#FI1691-3){ref-type="fig"} ).

![Forest plots of the included studies evaluating the feasibility of CbFAS.  **b** CE-IM rate, and **c** CE-D rate. CI, confidence interval; overall, overall effect size; random effect model; CE-IM, complete eradication of intestinal metaplasia; CE-D, complete eradication of dysplasia.](10-1055-a-1067-4520-i1691ei2){#FI1691-2}
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Complete eradication of intestinal metaplasia (CE-IM) and dysplasia (CE-D)
--------------------------------------------------------------------------

Among the seven studies consisting of 272 patients, CE-IM was reported in 228 following cryotherapy. The pooled proportion of CE-IM was 85.8 % (95 % CI: 77.8--92.2 %; *P*  = 0.04) with high degree of heterogeneity (I ^2^  = 55.5 %) ( [Fig. 2b](#FI1691-2){ref-type="fig"} ) and a 95 % prediction interval of 0.77--0.95. When the two low-quality studies [@JR1691-20] [@JR1691-21] were excluded, the pooled proportion of CE-IM was 87.7 % (95 % CI: 81.8--92.7 %; *P*  = 0.18) with moderate heterogeneity (I ^2^  = 36.2 %).

There were a total of 262 patients with dysplastic BE among the seven studies included in the meta-analysis. CE-D was reported in 238 of these patients following cryotherapy. The pooled proportion of CE-D was 93.8 % (95 % CI: 85.5--98.7 %; *P*  = 0.001) with I ^2^  = 74.2 % using a random-effects model ( [Fig. 2c](#FI1691-2){ref-type="fig"} ). The 95 % prediction interval was 0.84--1.04. When the two low-quality studies [@JR1691-20] [@JR1691-21] were excluded, the pooled proportion of CE-D was 93.1 % (95 % CI: 82.4--99.0; *P*  \< 0.001) with a still high degree of heterogeneity among the studies (I ^2^  = 82.8 %).

There was no evidence of substantial publication bias on the pooled proportions of CE-IM and CE-D on visual inspection of the funnel plots ( [Fig. 3b](#FI1691-3){ref-type="fig"} and [Fig. 3c](#FI1691-3){ref-type="fig"} ).

Adverse events
--------------

All studies reported post-procedural AEs. Among the seven studies in which 272 patients underwent BC, a total of 34 AEs (12.5 % of patients) were reported. In aggregate, there were 16 cases of post-ablation stricture formation (5.8 %), two severe cases of mucosal laceration (0.7 %), one case of perforation (0.4 %) and one case of gastrointestinal bleeding (0.4 %).

Discussion
==========

Cryotherapy has emerged as an endoscopic ablative option for patients with BE-associated neoplasia. Recently, a contact balloon cryotherapy device (CryoBalloon; Pentax Medical, Redwood City, California, United States) was introduced [@JR1691-8] . Our meta-analysis, which included seven studies comprising 272 patients with BE, demonstrated that BC was successful in achieving CE-IM in 88 % and CE-D in 94 % of patients.

Liquid nitrogen spray type (CSA Medical, Lexington, Massachusetts, United States) has been the most widely studied form of cryotherapy delivery method, as compared to the more recent BC. The majority of studies on spray cryotherapy have largely been retrospective, single-arm prospective or registry studies [@JR1691-25] [@JR1691-26] [@JR1691-27] [@JR1691-28] [@JR1691-29] . These studies suggest that spray cryotherapy may achieve similar CE-IM and CE-D rates when compared to RFA, and that cryotherapy is an effective option in those who have failed to respond to RFA [@JR1691-7] [@JR1691-30] . From a technical standpoint, spray cryotherapy facilitates treatment of large areas, but visualization for targeted therapy can be hindered by the cryogen spray obscuring the endoscopic lens. Furthermore, the gastrointestinal lumen must be intermittently decompressed with an external tube to prevent excess gas accumulation during treatment. Lastly, the device requires capital investment, which must be factored from a cost perspective.

The BC is a portable device that is self-venting, as the cryogen spray is contained within the balloon that contacts the targeted area in the esophagus. Our meta-analysis demonstrated that ablation with BC was successfully performed in 96 % of patients, even though most of the included studies used the earlier version of the system. Since then, next-generation CryoBalloon devices have been introduced, including the addition of a pear-shaped balloon to assist with contact treatment at the gastroesophageal junction and wider field cryogen probes to target larger areas. We can only speculate that these next-generation CryoBalloon systems will further enhance ease of use and widen its application [@JR1691-31] , still, further data are needed on both technique and optimal dosing strategies.

The primary aim of this meta-analysis was to evaluate the effectiveness of BC for treatment of patients with BE. Our study demonstrated that BC was associated with high rates of CE-IM (88 %) and CE-D (94 %). We calculated the 95 % prediction intervals to evaluate the variability of the effect of ablation that are likely to be seen in other patients. The interval for CE-IM 0.77--0.95 shows a narrow and favorable range of effect in future potential patients. Because of a higher between study heterogeneity, the prediction interval for CE-D was found to be 0.84--1.04. This range covering the null effect again underscores the need for further larger studies. Given the limited literature and relatively small number of patients, we included all studies involving BC for patients with BE. This strategy may have introduced heterogeneity as both treatment naïve and RFA non-responders were included in the analysis. Nonetheless, our findings suggest that BC is highly effective for the treatment of BE, even when including cohort of patients who have previously failed RFA. Future larger studies are needed to better define the role of BC as a primary or secondary endoscopic ablative technique in BE associated neoplasia.

Our study suggests that BC is associated with an acceptable safety profile, with an overall AE rate of 12.5 %. In this meta-analysis, post-procedural stricture formation was noted in 5.8 % of patients, which is comparable with the 5 % esophageal structuring rate reported after RFA [@JR1691-2] . Furthermore, there were only two cases of serious AEs (1 perforation and 1 GI bleeding) reported with BC. Overall, our meta-analysis suggests that the post-procedural AEs with BC are similar to those for both RFA and spray cryotherapy [@JR1691-2] [@JR1691-27] [@JR1691-28] [@JR1691-29] .

We acknowledge the limitations of this meta-analysis. Given the relative novelty of BC for the treatment of BE, all of the included studies were relatively small, observational, and many had only been published in abstract form alone. As previously alluded, the pooled proportions of CE-IM and CE-D included both treatment naïve and RFA refractory patients with BE, which contributed to the heterogeneity noted in the analysis and the possibility of confounding of the effectiveness outcome. Moreover, conducting a meta-analysis of observational studies presents challenges in interpreting the study outcome due to the inherent biases in the included studies. In this study confounding biases may include the aforementioned lack of reporting of patient treatment with RFA in two studies and reporting of treatment duration to name a few. Publication bias, as in the selection of publications based on their cohort size and language of publication should also be considered. This study reports funnel plots to aid in detection of publication bias, however, the lack of sensitivity analysis for confounders presents a limitation of this study [@JR1691-13] .

Furthermore, many of the studies evaluated clinical outcomes following only one session of BC. The relatively short follow-up precludes any definitive conclusions on the effectiveness of BC in maintaining CE-IM and CE-D and the potential rate of incomplete treatment vs recurrence rates. Nonetheless, this meta-analysis of the current available literature on BC is promising, albeit underscores the need for high-quality studies.

Conclusion
==========

In summary, this meta-analysis suggests that BC is technically feasible and associated with high rates of both CE-IM and CE-D in patients with BE. BC has a similar safety profile to both spray cryotherapy and RFA, with stricture formation encountered in approximately 6 % of patients. The cryoablation balloon is a novel, portable, easy-to-use device that may be suitable for primary and secondary treatment of patients with BE. Larger prospective, and preferably comparative trials are needed to further define the role of BC in the treatment algorithm of patients with BE-associated neoplasia.
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